Ning Li
机构:Shenyang Pharmaceutical University, University of Fukui, Central South University, Shanxi Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Southern University of Science and Technology, Zhengzhou University, First Affiliated Hospital of Xiamen University, National Cancer Center, Shanghai University of Traditional Chinese Medicine, Jiangxi Provincial People's Hospital, Taihe Hospital, National Cancer Registry, National Clinical Research, Second Hospital of Shanxi Medical University, Shanghai Traditional Chinese Medicine Hospital, Henan Cancer Hospital, Xiangya Hospital Central South University, Affiliated Hospital of Jining Medical University, Shenzhen Third People’s Hospital, Jinzhou Medical University · ORCID:0000-0002-3266-3322
发表论文 154 篇 · 总被引 2293 次 · h-index 27
代表论文
- Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation (2025 · Molecular Cancer · 被引 65)
- Recent advances in universal chimeric antigen receptor T cell therapy (2025 · Journal of Hematology & Oncology · 被引 28)
- A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights (2024 · Nature Communications · 被引 27)
- Melittin suppresses ovarian cancer growth by regulating SREBP1-mediated lipid metabolism (2025 · Phytomedicine · 被引 18)
- Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects (2025 · Cancer Cell International · 被引 9)
- Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III trial (2024 · Gynecologic Oncology · 被引 7)